Inventor · disambiguated record
Frank Beurskens
Also filed as: BEURSKENS FRANK
13 granted patents·35 pending applications·63 citations·filing 2004–2025
91Inventor score
Top patents by PatentIndex Score
48 records- 0197US12049512B2Antibody variants and uses thereofGENMAB BV·Filed 2020·Granted Jul 30, 2024·5 cites·17 claims
- 0295US11396553B2Bispecific anti-CD37 antibodies, monoclonal anti-CD37 antibodies and methods of use thereofGENMAB HOLDING B V·Filed 2021·Granted Jul 26, 2022·8 cites·23 claims
- 0394US11512137B2Bispecific anti-CD37 antibodies, monoclonal anti-CD37 antibodies and methods of use thereofGENMAB HOLDING B V·Filed 2020·Granted Nov 29, 2022·10 cites·10 claims
- 0494US11034772B2Bispecific anti-CD37 antibodies, monoclonal anti-CD37 antibodies and methods of use thereofGENMAB HOLDING B V·Filed 2020·Granted Jun 15, 2021·7 cites·20 claims
- 0593US10759867B2Antibody variants and uses thereofPARREN PAUL·Filed 2012·Granted Sep 1, 2020·14 cites·6 claims
- 0691US11180572B2Dimeric protein with triple mutationsGENMAB BV·Filed 2013·Granted Nov 23, 2021·12 cites·45 claims
- 0785US2025223374A1Antibody variants and uses thereofGENMAB BV·Filed 2024·Application pending·0 cites
- 0884US2025043018A1Antibody variants and uses thereofPARREN PAUL·Filed 2024·Application pending·0 cites
- 0982US10351629B2Recombinant IgG4 monovalent antibodiesGENMAB AS·Filed 2016·Granted Jul 16, 2019·2 cites·24 claims
- 1080US2024117064A1Bispecific anti-cd37 antibodies, monoclonal anti-cd37 antibodies and methods of use thereofGENMAB HOLDING B V·Filed 2022·Application pending·0 cites
- 1179US9322035B2Recombinant IgG4 monovalent antibodiesSCHUURMAN JANINE·Filed 2008·Granted Apr 26, 2016·2 cites·6 claims
- 1277US12448459B2Bispecific anti-CD37 antibodies, monoclonal anti-CD37 antibodies and methods of use thereofGENMAB HOLDING B V·Filed 2021·Granted Oct 21, 2025·0 cites·23 claims
- 1377US2024317881A1Variants of cd38 antibody and uses thereofGENMAB AS·Filed 2024·Application pending·0 cites
- 1476US2025145720A1Human igg1 fc region variants and uses thereofGENMAB BV·Filed 2024·Application pending·0 cites
- 1576US2022411522A1Anti-death receptor antibodies and methods of use thereofGENMAB BV·Filed 2022·Application pending·0 cites
- 1675US12173076B2Polypeptide variants and uses thereofGENMAB BV·Filed 2018·Granted Dec 24, 2024·1 cites·15 claims
- 1773US10155816B2Recombinant monovalent antibodies and methods for production thereofPARREN PAUL·Filed 2006·Granted Dec 18, 2018·1 cites·17 claims
- 1873US2025326854A1Polypeptide variants and uses thereofGENMAB BV·Filed 2024·Application pending·0 cites
- 1973US2023212301A1Antibodies capable of binding to cd27, variants thereof and uses thereofGENMAB BV·Filed 2022·Application pending·0 cites
- 2072US12275797B2Anti-CD37 antibodies and anti-CD20 antibodies, compositions and methods of use thereofGENMAB HOLDING B V·Filed 2019·Granted Apr 15, 2025·1 cites·18 claims
- 2172US2023109496A1Antibodies capable of binding to cd27, variants thereof and uses thereofGENMAB BV·Filed 2022·Application pending·0 cites
- 2272US2022396629A1Recombinant monovalent antibodies and methods for production thereofGENMAB AS·Filed 2022·Application pending·0 cites
- 2371US2025289900A1Antibodies capable of binding to cd27, variants thereof and uses thereofGENMAB AS·Filed 2025·Application pending·0 cites
- 2471US2025289899A1Antibodies capable of binding to cd27, variants thereof and uses thereofGENMAB AS·Filed 2025·Application pending·0 cites
- 2566US2023107363A1Polypeptide variants and uses thereofGENMAB BV·Filed 2022·Application pending·0 cites
- 2664US2022332801A1Antibodies and methods of use thereof in treatment of infectious diseaseGENMAB BV·Filed 2021·Application pending·0 cites
- 2764US2020270359A1Bispecific anti-cd37 antibodies, monoclonal anti-cd37 antibodies and methods of use thereofGENMAB HOLDING BV·Filed 2018·Application pending·0 cites
- 2861US2019202926A1Anti-death receptor antibodies and methods of use thereofGENMAB BV·Filed 2016·Application pending·0 cites
- 2961US2020017600A1Variants of cd38 antibody and uses thereofGENMAB AS·Filed 2019·Application pending·0 cites
- 3060US2020165352A1Variants of cd38 antibody and uses thereofGENMAB AS·Filed 2020·Application pending·0 cites
- 3159US2023399414A1Bispecific anti-cd37 antibodies, monoclonal anti-cd37 antibodies and methods of use thereofGENMAB HOLDING B V·Filed 2022·Application pending·0 cites
- 3259US2025325643A1Binding agents capable of binding to cd27 in combination therapyGENMAB AS·Filed 2023·Application pending·0 cites
- 3358US2009155204A1Methods for treating disorders involving monocytesGENMAB AS·Filed 2008·Application pending·0 cites
- 3457US2019169298A1Recombinant monovalent antibodies and methods for production thereofGENMAB AS·Filed 2018·Application pending·0 cites
- 3554US2005123542A1Methods for treating disorders involving monocytesGENMAB AS·Filed 2004·Application pending·0 cites
- 3652US2015353636A1Human igg1 fc region variants and uses thereofGENMAB BV·Filed 2013·Application pending·0 cites
- 3751US2021230301A1Dimeric protein with triple mutationsGENMAB BV·Filed 2020·Application pending·0 cites
- 3851US2010255012A1Recombinant fucose modified monovalent half-antibodies obtained by molecular engineeringGENMAB AS·Filed 2008·Application pending·0 cites
- 3950US2020123237A1Antibodies and methods of use thereof in treatment of infectious diseaseGENMAB BV·Filed 2017·Application pending·0 cites
- 4049US12338289B2Antibody variant combinations and uses thereofGENMAB BV·Filed 2019·Granted Jun 24, 2025·0 cites·17 claims
- 4149US2010325744A1Non-glycosylated recombinant monovalent antibodiesGENMAB AS·Filed 2008·Application pending·0 cites
- 4249US2011045007A1Fusion or linked proteins with extended half lifeGENMAB AS·Filed 2008·Application pending·0 cites
- 4349US2010291023A1Method for extending the half-life of exogenous or endogenous soluble moleculesGENMAB AS·Filed 2008·Application pending·0 cites
- 4448US2022411529A1Antibody variant combinations and uses thereofGENMAB BV·Filed 2020·Application pending·0 cites
- 4547US2019276549A1Polypeptide variants and uses thereofGENMAB BV·Filed 2017·Application pending·0 cites
- 4646US2024252635A1Pharmaceutical compositions comprising bispecific anti-cd37 antibodiesGENMAB HOLDING B V·Filed 2019·Application pending·0 cites
- 4746US2024254252A1Trogocytosis-mediated therapy using cd38 antibodiesGENMAB AS·Filed 2019·Application pending·0 cites
- 4844US2021107988A1Polypeptide variants and uses thereofGENMAB BV·Filed 2019·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Frank Beurskens files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →